Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement

Oncology. 2018;94 Suppl 1(Suppl 1):6-9. doi: 10.1159/000489062. Epub 2018 Jul 23.

Abstract

We report the case of a 50-year-old woman with a triple-negative Ki67 80% breast cancer with liver metastases, who obtained a radiological long-lasting complete response after treatment with eribulin. The patient initially experienced progressive disease after a standard anthracycline/taxane-based adjuvant chemotherapy, a first-line treatment for metastatic disease with paclitaxel-bevacizumab, and a second-line maintenance treatment with bevacizumab and capecitabine. Eribulin was administered according to a 1.23 mg/m2 scheme on days 1 and 8 every 3 weeks, and the treatment was always well tolerated. After 45 cycles of therapy, we still detected radiological evidence of complete response on liver sites of disease. This case report underlines the great efficacy of eribulin as third-line treatment for metastatic disease in a very aggressive form of breast cancer.

Keywords: Complete response; Eribulin; Liver metastases; Triple-negative breast cancer.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant / methods
  • Female
  • Furans / therapeutic use*
  • Humans
  • Ketones / therapeutic use*
  • Liver / drug effects*
  • Liver / pathology
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Middle Aged
  • Polyether Polyketides
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Furans
  • Ketones
  • eribulin
  • Polyether Polyketides